Gilead's Sovaldi, Harvoni Get Exclusive HCV Placement On CVS/Caremark Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
CVS Health’s pharmacy benefit management subsidiary has opted for full coverage of Gilead’s hepatitis C virus drugs over AbbVie’s combination HCV drug Viekira Pak on its commercial formularies for 2015, citing them as the “lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C.”